FeesSafety
Pluang+

Compare Crispr Therapeutics AG (CRSP) vs Wynn Resorts, Limited (WYNN) Price & Performance

Crispr Therapeutics AGTrade
Wynn Resorts, LimitedTrade

Price performance (Past 24H)

Key statistics

Crispr Therapeutics AG vs Wynn Resorts, Limited — how do they compare? Crispr Therapeutics AG trades at $40.56 (market cap $4.10B), while Wynn Resorts, Limited trades at $82.05 (market cap $8.76B). The key difference: Wynn Resorts, Limited is far larger — about 2.1× Crispr Therapeutics AG's market cap, and Wynn Resorts, Limited pays a 1.18% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 79 Days and Wynn Resorts, Limited for 77 Days on average.

CRSPWYNN
Market Cap
$4.10B$8.76B
Volume
1,873,7751,820,173
Sector
HealthConsumer Cyclical
52-Week High
$61.89$133.09
52-Week Low
$42.24$71.38
Typical Hold Time
79 Days77 Days
Enterprise Value
$2.60B$19.32B
Dividend Yield
—1.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Crispr Therapeutics AG

CRISPR Therapeutics (CRSP) trades at $40.37, down 4.43% amid bearish technical signals despite strong analyst support. The company shows negative profitability with -1,955.73% net income margin and -$581.60M net loss for 2025, though revenue growth from CASGEVY commercialization provides long-term potential. Recent clinical data presentations and pipeline catalysts through year-end 2026 offer near-term momentum drivers.

While CRSP faces significant financial losses and cash burn, Wall Street maintains bullish sentiment with 57.9% buy ratings and $72.43 consensus target implying 79% upside. Investment thesis hinges on successful commercialization of gene-editing therapies, though execution risks and sustained losses require careful risk management for investors seeking biotech growth exposure.

Wynn Resorts, Limited

Wynn Resorts (WYNN) trades at $81.65, down 4.01% today, amid mixed quarterly results with Q2 2026 beating estimates but Q3 missing. The stock shows bullish technical signals with moving averages supporting upward momentum, though RSI indicates potential overbought conditions. Revenue growth has stabilized around $7.1B annually, but net margins have compressed from 11.2% in 2023 to 4.6% in 2025. Recent news highlights institutional buying interest and the company's $900 million senior notes offering to fund expansion projects.

Wynn presents a compelling risk-reward profile with strong analyst support (65% buy ratings) and a $116 price target implying 42% upside. However, high debt levels ($10.5B long-term), margin pressure, and significant capital expenditures for UAE and Macau projects create execution risks. The stock's valuation at 24x P/E appears reasonable given recovery potential, but investors must weigh growth opportunities against financial leverage and cyclical casino exposure.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CRSP
66% Buy34% Sell
Avg holding period · 79 Days
WYNN

No sentiment data available yet.

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP →

About Wynn Resorts, Limited

Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.

Read more on WYNN →